Evotec Selling And Marketing Expenses vs Operating Income Analysis

EVO Stock

USD 4.88 0.12 2.40%

Evotec SE financial indicator trend analysis is much more than just examining Evotec SE ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evotec SE ADR is a good investment. Please check the relationship between Evotec SE Selling And Marketing Expenses and its Operating Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Selling And Marketing Expenses vs Operating Income

Selling And Marketing Expenses vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evotec SE ADR Selling And Marketing Expenses account and Operating Income. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Evotec SE's Selling And Marketing Expenses and Operating Income is -0.17. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Evotec SE ADR, assuming nothing else is changed. The correlation between historical values of Evotec SE's Selling And Marketing Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Evotec SE ADR are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Selling And Marketing Expenses i.e., Evotec SE's Selling And Marketing Expenses and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.17

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Selling And Marketing Expenses

Operating Income

Operating Income is the amount of profit realized from Evotec SE ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Evotec SE ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Evotec SE's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evotec SE ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

At this time, Evotec SE's Selling General Administrative is very stable compared to the past year. As of the 27th of December 2024, Sales General And Administrative To Revenue is likely to grow to 0.26, while Tax Provision is likely to drop about 3.2 M.

	2021	2022	2023	2024 (projected)
Total Revenue	618.0M	751.4M	781.4M	820.5M
Depreciation And Amortization	67.6M	81.7M	167.9K	159.5K

Total Revenue Depreciation And Amortization

Evotec SE fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Other Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Net Receivables	Inventory
Total Assets		0.99	-0.24	0.8	-0.59	0.96	0.95	0.95	0.96	0.29	0.33	0.94	0.96	0.99	0.9	0.96	0.64	0.97	0.89	0.99	0.98	0.52	0.6	0.97	0.92	0.95
Total Stockholder Equity	0.99		-0.22	0.82	-0.52	0.92	0.92	0.91	0.93	0.14	0.36	0.9	0.97	0.96	0.87	0.98	0.68	0.92	0.9	0.94	0.99	0.47	0.6	0.97	0.89	0.94
Common Stock Shares Outstanding	-0.24	-0.22		0.12	0.45	-0.32	-0.17	-0.11	-0.28	-0.12	-0.85	-0.19	-0.31	-0.21	-0.18	-0.3	-0.15	-0.33	-0.28	-0.26	-0.28	0.16	0.49	-0.26	-0.46	-0.41
Other Stockholder Equity	0.8	0.82	0.12		-0.23	0.72	0.76	0.71	0.7	0.06	0.02	0.68	0.78	0.76	0.69	0.82	0.7	0.74	0.77	0.75	0.82	0.3	0.88	0.8	0.64	0.66
Other Assets	-0.59	-0.52	0.45	-0.23		-0.57	-0.55	-0.63	-0.75	-0.54	-0.32	-0.76	-0.42	-0.62	-0.68	-0.47	-0.45	-0.64	-0.64	-0.65	-0.54	-0.4	0.05	-0.55	-0.78	-0.75
Short Long Term Debt Total	0.96	0.92	-0.32	0.72	-0.57		0.94	0.92	0.93	0.45	0.33	0.89	0.93	0.97	0.86	0.91	0.5	0.98	0.81	0.98	0.93	0.53	0.56	0.92	0.9	0.9
Other Current Liab	0.95	0.92	-0.17	0.76	-0.55	0.94		0.92	0.89	0.4	0.29	0.87	0.89	0.96	0.8	0.9	0.59	0.95	0.84	0.96	0.92	0.51	0.64	0.95	0.9	0.87
Total Current Liabilities	0.95	0.91	-0.11	0.71	-0.63	0.92	0.92		0.94	0.41	0.22	0.96	0.86	0.98	0.9	0.84	0.48	0.89	0.78	0.95	0.88	0.76	0.56	0.89	0.85	0.92
Property Plant And Equipment Net	0.96	0.93	-0.28	0.7	-0.75	0.93	0.89	0.94		0.37	0.27	0.99	0.89	0.97	0.95	0.9	0.58	0.95	0.86	0.97	0.93	0.56	0.48	0.91	0.92	0.97
Net Debt	0.29	0.14	-0.12	0.06	-0.54	0.45	0.4	0.41	0.37		-0.1	0.37	0.1	0.38	0.34	0.09	0.0	0.44	0.21	0.44	0.17	0.45	0.13	0.24	0.42	0.29
Retained Earnings	0.33	0.36	-0.85	0.02	-0.32	0.33	0.29	0.22	0.27	-0.1		0.2	0.4	0.29	0.16	0.4	0.28	0.32	0.35	0.29	0.38	-0.07	-0.35	0.4	0.5	0.46
Accounts Payable	0.94	0.9	-0.19	0.68	-0.76	0.89	0.87	0.96	0.99	0.37	0.2		0.85	0.96	0.95	0.85	0.53	0.9	0.82	0.95	0.89	0.65	0.48	0.87	0.88	0.95
Cash	0.96	0.97	-0.31	0.78	-0.42	0.93	0.89	0.86	0.89	0.1	0.4	0.85		0.93	0.82	0.98	0.56	0.92	0.82	0.92	0.97	0.41	0.57	0.93	0.83	0.89
Non Current Assets Total	0.99	0.96	-0.21	0.76	-0.62	0.97	0.96	0.98	0.97	0.38	0.29	0.96	0.93		0.92	0.92	0.56	0.96	0.85	0.99	0.95	0.61	0.58	0.95	0.91	0.94
Non Currrent Assets Other	0.9	0.87	-0.18	0.69	-0.68	0.86	0.8	0.9	0.95	0.34	0.16	0.95	0.82	0.92		0.83	0.53	0.88	0.8	0.91	0.86	0.58	0.49	0.86	0.83	0.91
Cash And Short Term Investments	0.96	0.98	-0.3	0.82	-0.47	0.91	0.9	0.84	0.9	0.09	0.4	0.85	0.98	0.92	0.83		0.72	0.92	0.9	0.92	0.99	0.34	0.58	0.96	0.88	0.91
Short Term Investments	0.64	0.68	-0.15	0.7	-0.45	0.5	0.59	0.48	0.58	0.0	0.28	0.53	0.56	0.56	0.53	0.72		0.6	0.85	0.57	0.72	-0.05	0.45	0.7	0.72	0.64
Non Current Liabilities Total	0.97	0.92	-0.33	0.74	-0.64	0.98	0.95	0.89	0.95	0.44	0.32	0.9	0.92	0.96	0.88	0.92	0.6		0.87	0.99	0.95	0.43	0.55	0.95	0.94	0.92
Other Current Assets	0.89	0.9	-0.28	0.77	-0.64	0.81	0.84	0.78	0.86	0.21	0.35	0.82	0.82	0.85	0.8	0.9	0.85	0.87		0.86	0.92	0.28	0.51	0.89	0.92	0.88
Total Liab	0.99	0.94	-0.26	0.75	-0.65	0.98	0.96	0.95	0.97	0.44	0.29	0.95	0.92	0.99	0.91	0.92	0.57	0.99	0.86		0.95	0.56	0.57	0.95	0.93	0.94
Total Current Assets	0.98	0.99	-0.28	0.82	-0.54	0.93	0.92	0.88	0.93	0.17	0.38	0.89	0.97	0.95	0.86	0.99	0.72	0.95	0.92	0.95		0.39	0.59	0.97	0.91	0.94
Short Term Debt	0.52	0.47	0.16	0.3	-0.4	0.53	0.51	0.76	0.56	0.45	-0.07	0.65	0.41	0.61	0.58	0.34	-0.05	0.43	0.28	0.56	0.39		0.31	0.38	0.38	0.54
Common Stock	0.6	0.6	0.49	0.88	0.05	0.56	0.64	0.56	0.48	0.13	-0.35	0.48	0.57	0.58	0.49	0.58	0.45	0.55	0.51	0.57	0.59	0.31		0.59	0.36	0.36
Current Deferred Revenue	0.97	0.97	-0.26	0.8	-0.55	0.92	0.95	0.89	0.91	0.24	0.4	0.87	0.93	0.95	0.86	0.96	0.7	0.95	0.89	0.95	0.97	0.38	0.59		0.92	0.91
Net Receivables	0.92	0.89	-0.46	0.64	-0.78	0.9	0.9	0.85	0.92	0.42	0.5	0.88	0.83	0.91	0.83	0.88	0.72	0.94	0.92	0.93	0.91	0.38	0.36	0.92		0.95
Inventory	0.95	0.94	-0.41	0.66	-0.75	0.9	0.87	0.92	0.97	0.29	0.46	0.95	0.89	0.94	0.91	0.91	0.64	0.92	0.88	0.94	0.94	0.54	0.36	0.91	0.95

Click cells to compare fundamentals

Evotec SE Account Relationship Matchups

Evotec SE fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.2B	1.5B	2.2B	2.3B	2.3B	2.4B
Total Stockholder Equity	477.0M	722.8M	1.4B	1.2B	1.1B	1.2B
Common Stock Shares Outstanding	151.5M	153.8M	166.4M	176.7M	176.9M	188.3M
Liabilities And Stockholders Equity	1.2B	1.5B	2.2B	2.3B	2.3B	2.4B
Other Stockholder Equity	786.9M	1.0B	1.4B	1.4B	1.4B	733.8M
Other Assets	58.0M	62.3M	79.3M	1.0	1.15	1.09
Short Long Term Debt Total	463.1M	492.0M	512.9M	506.7M	626.2M	657.5M
Other Current Liab	53.5M	61.9M	63.9M	78.4M	73.3M	77.0M
Total Current Liabilities	179.0M	208.5M	324.5M	337.7M	464.6M	487.8M
Property Plant And Equipment Net	239.2M	337.3M	484.6M	650.2M	806.6M	846.9M
Net Debt	186.1M	69.8M	(186.4M)	91.5M	115.3M	121.1M
Retained Earnings	(441.2M)	(434.2M)	(216.4M)	(392.4M)	(476.3M)	(500.1M)
Accounts Payable	31.3M	42.5M	72.6M	97.3M	134.3M	141.0M
Cash	277.0M	422.2M	699.3M	415.2M	510.9M	536.5M
Non Current Assets Total	711.4M	804.1M	1.1B	1.2B	1.4B	1.5B
Non Currrent Assets Other	23.7M	37.4M	56.8M	74.1M	95.2M	100.0M
Cash And Short Term Investments	321.7M	492.2M	858.5M	730.0M	604.1M	634.3M
Short Term Investments	44.6M	70.1M	159.2M	314.8M	93.2M	74.6M
Non Current Liabilities Total	524.9M	531.6M	533.0M	732.4M	714.6M	750.3M
Other Current Assets	3.8M	62.8M	63.6M	123.0M	64.1M	67.3M
Total Liab	703.9M	740.0M	857.5M	1.1B	1.2B	1.2B
Total Current Assets	469.5M	658.8M	1.1B	1.1B	903.2M	948.3M
Short Term Debt	20.7M	30.0M	50.6M	16.4M	149.1M	156.5M
Common Stock	150.9M	163.9M	176.6M	177.0M	177.2M	128.1M
Current Deferred Revenue	73.4M	70.6M	126.8M	136.7M	107.9M	113.2M
Net Receivables	124.1M	136.9M	153.3M	275.8M	204.1M	214.3M
Inventory	10.7M	13.6M	25.8M	29.8M	30.9M	32.4M
Good Will	255.9M	247.4M	257.6M	274.8M	275.6M	289.4M
Intangible Assets	117.0M	98.0M	30.9M	23.8M	15.5M	14.7M
Accumulated Other Comprehensive Income	(19.6M)	(37.5M)	(12.6M)	(37.4M)	(30.6M)	(32.2M)
Other Liab	93.2M	82.6M	69.6M	70.7M	63.6M	61.8M
Net Tangible Assets	79.0M	102.9M	375.9M	1.1B	1.3B	1.3B
Long Term Debt	324.9M	331.0M	326.3M	328.3M	307.1M	266.0M
Capital Lease Obligations	131.9M	145.6M	150.4M	176.8M	189.1M	125.8M
Net Invested Capital	808.3M	1.1B	1.7B	1.5B	1.1B	1.1B
Short Long Term Debt	6.3M	15.4M	36.1M	1.6M	130.0M	136.5M
Net Working Capital	290.6M	450.4M	776.4M	736.0M	438.6M	421.1M
Property Plant Equipment	89.3M	238.0M	335.7M	484.6M	557.3M	585.2M
Long Term Investments	41.3M	59.0M	287.0M	150.3M	142.1M	129.9M
Capital Stock	150.9M	163.9M	176.6M	177.0M	177.2M	182.3M

Pair Trading with Evotec SE

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.

Moving against Evotec Stock

0.81	ME	23Andme Holding	Pair Corr
0.74	VALN	Valneva SE ADR	Pair Corr
0.71	DRRX	Durect	Pair Corr
0.69	DTIL	Precision BioSciences	Pair Corr
0.68	DRMA	Dermata Therapeutics	Pair Corr

The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.

The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evotec SE ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evotec SE's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evotec Se Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evotec Se Adr Stock:

How To Invest In Evotec

Details

Is Evotec Stock a good investment?

Details

What is Evotec SE's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.50)

Revenue Per Share

2.1925

Quarterly Revenue Growth

(0.06)

Return On Assets

(0.02)

Return On Equity

(0.16)

The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evotec Selling And Marketing Expenses vs Operating Income Analysis

Selling And Marketing Expenses vs Operating Income

Selling And Marketing Expenses vs Operating Income Correlation Analysis

Correlation Coefficient

Selling And Marketing Expenses

Operating Income

Evotec SE fundamental ratios Correlations

Evotec SE Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evotec SE fundamental ratios Accounts

Pair Trading with Evotec SE

Moving against Evotec Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Accounts Payable	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.99	Non Current Assets Total

Retained Earnings	- 0.85	Common Stock Shares Outstanding
Net Receivables	- 0.78	Other Assets
Accounts Payable	- 0.76	Other Assets
Inventory	- 0.75	Other Assets
Property Plant And Equipment Net	- 0.75	Other Assets
Non Currrent Assets Other	- 0.68	Other Assets